KY-1044
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
COA:
Inquire
Targets:
ICOS
Description:
KY-1044 is a novel anti-inducible co-stimulator molecule (ICOS) subclass G1 kappa monoclonal antibody developed for the treatment of cancer. KY-1044 has a dual mechanism of action: stimulating immune cells which are fighting the tumor, while also killing a type of cell known as T regulatory cells (Tregs).
Publication citing BOC Sciences Products
1. Effects of hypercapnia on T cells in lung ischemia/reperfusion injury after lung transplantation
2. Betulin-based thermoplastics and thermosets through sustainable and industrially viable approaches: new insights for the valorization of an underutilized resource
3. Drug "Pent‐Up" in Hollow Magnetic Prussian Blue Nanoparticles for NIR‐Induced Chemo‐Photothermal Tumor Therapy with Trimodal Imaging
4. Bio-Wax Latex-Modified Paper as Antimicrobial and Water-Vapor-Resistant Packaging Material
5. Study of the chromatographic behavior of selected antipsychotic drugs on RP-TLC based on quantitative structure–retention relationships
6. Total synthesis of diazaquinomycins H and J using double Knorr cyclization in the presence of triisopropylsilane

>> More

Brife Description:
G1 kappa monoclonal antibody
Synonyms:
KY-1044; KY1044; KY1044
MSDS:
Inquire
Application:
potential cancer therapy
Current Developer:
Kymab
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related ICOS Products

KY-1044

KY-1044 is a novel anti-inducible co-stimulator molecule (ICOS) subclass G1 kappa monoclonal antibody developed for the treatment of cancer. KY-1044 has a dual ...

Quick Inquiry

Verification code

Featured Items